The bill’s goal is to rein in the skyrocketing cost of pharmaceuticals without running afoul of U.S. patent law, which allows drugmakers to hold a monopoly and pricing advantage for years after they patent a new medication. Federal courts struck down a D.C. drug-affordability law passed in 2005, which …
